Summary
Premature aging of both CD4 + regulatory T (Treg) and CD4 + responder-T (Tresp) cells in patients with end-stage renal disease (ESRD) is expected to affect the success of later kidney transplantation. Both T-cell populations are released from the thymus as inducible T-cell co-stimulator- 
Introduction
Chronic kidney disease is characterized by a progressive loss of renal function. The final stage, classified as end-stage renal disease (ESRD), requires replacement therapies, which cannot completely restore renal function. Consequently, the accumulation of uraemic toxins favours the occurrence of immunological disorders, [1] [2] [3] with the T-cell compartment being most affected. [4] [5] [6] [7] [8] [9] [10] [11] A lower thymic output and therefore an increased differentiation and premature aging Abbreviations: ESRD, end-stage renal disease; ICOS, inducible T-cell co-stimulator; MN, mature naive; RTE, recent thymic emigrant; Treg, regulatory T; Tresp, responder T
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of the T-cells are already documented. [12] [13] [14] [15] Thereby, both responder T (Tresp) and regulatory T (Treg) cells, 16 which normally suppress the function of activated Tresp cells, are affected. Kidney transplantation is the preferred method of renal replacement therapy, as, compared with dialysis, it reduces mortality and improves long-term survival. 17, 18 In particular, it was suggested that chronic inflammation was improved by restoring kidney function. 19 However, with increasing time after transplantation, most transplant recipients revert to renal insufficiency. 20 As the advanced aging of the T cells cannot be reversed, a further impairment of the T-cell compartment has to be expected. 21. Currently, the effects of renal insufficiency and its recovery on the differentiation and functionality of T cells are not sufficiently understood. Different subsets of Treg and Tresp cells are likely to be influenced differently. The most prominent naturally occurring Treg cell populations differ concerning their expression of the inducible T-cell costimulator (ICOS) molecule, which is already expressed in the thymus. Their induction by dendritic cells, proliferation and survival were shown to be regulated differentially. 22, 23 In addition to its expression on Treg cells, the ICOS molecule is also expressed on Tresp cells and it was shown that both ICOS + Treg/Tresp cells and ICOS À Treg/Tresp cells are released from the thymus as CD45RA + CD31 + recent thymic emigrant (RTE) Treg/Tresp cells. 24 Normally, RTE T cells undergo peripheral post-thymic proliferation to form a long-living CD45RA + CD31 À mature naive (MN) T-cell population, which has the capacity to maintain the naive Tcell pool throughout adult life. 25, 26 After stimulation with appropriate antigens, both RTE and MN T cells differentiate into memory T cells. 27 Recently, we demonstrated that different differentiation pathways affect the suppressive activity of Treg cells on autologous Tresp cells differentially and therefore had a decisive role for the maintenance of Treg cell function during both pregnancy and renal insufficiency. 28, 29 In this study, we examined the influence of renal insufficiency and the subsequent renal replacement therapies on the differentiation of ICOS + 
Materials and methods

Patient collectives
For quantitative analysis, peripheral blood samples were collected from 156 healthy volunteers, 49 ESRD patients before initiation of dialysis therapy, 61 dialysis patients and 196 renal transplant recipients. The blood samples from ESRD patients were taken a few days before the start of the dialysis therapy. Blood samples from dialysis patients were obtained at the beginning of the repeated dialysis treatment. These patients did not show recent illness (within the previous 3 months) or significant anaemia and had not received any immunosuppressive drugs. Blood samples from stable kidney transplant patients (inconspicuous creatinine levels and glomerular filtration rate, no clinical signs of renal failure) were collected during routine control checks. Kidney transplant recipients were subdivided into two different groups, one group containing 103 patients who had undergone kidney transplantation < 2 years before participation in the study and one group consisting of 93 recipients > 2 years post transplantation. Exclusion criteria included infectioninduced graft failure, post-renal obstruction or druginduced renal failure. For functional analysis, we collected 10 healthy volunteers, 10 ESRD patients, 10 dialysis patients and 22 kidney transplant recipients (n (< 2 years) = 11 and n (> 2 years) = 11). Clinical characteristics of all participants are summarized in Table 1 . The study was approved by the Regional Ethics Committee. All participants were fully informed of the aim of the study and written informed consent was obtained from all participants.
Fluorescence-activated cell sorter staining
Venous blood samples (9 ml) from all participants were collected into EDTA-containing tubes. Whole peripheral blood mononuclear cells were isolated by Lymphodex (Inno-Train Diagnostik GMBH, Kronberg, Germany) gradient centrifugation and analysed by six-colour flow cytometric analysis. Briefly, peripheral blood mononuclear cells (8 9 10 6 cells) were surface-stained with 10 ll peridinin chlorophyll protein-conjugated anti-CD4 (BD Bioscience, Heidelberg, Germany), 5 ll phycoerythrin-Cy7-conjugated anti-CD127 (eBioscience, Frankfurt, Germany), 5 ll Alexa Fluor 647-conjugated anti-CD31 (BD Bioscience), 5 ll allophycocyanin (APC-H7)-conjugated anti-CD45RA (BD Bioscience) and 20 ll phycoerythrin-conjugated anti-CD278 (ICOS) (BD Bioscience) mouse monoclonal antibodies. Subsequently, intracellular staining was performed for the detection of FoxP3 using a fluorescein isothiocyanate-labelled antihuman FoxP3 staining set (clone PCH101; eBioscience), according to the manufacturer's instructions. Negative control samples were incubated with isotype-matched antibodies. Dead cells were excluded by forward-and side-scatter characteristics. Cells were analysed on a FACS Canto cytometer (BD Bioscience). Statistical analysis was based on at least 100 000 gated CD4 + T cells. at Treg measurement
The data are presented as their median values together with their range (minimum-maximum). ATG, antithymocyte globulin; CKD-EPI GFR, chronic kidney disease epidemiology collaboration estimated glomerular filtration rate; CsA, cyclosporin; GN, glomerulonephritis; HD, haemodialysis; MPA, mycophenolic acid; mTOR-inh., mechanistic target of rapamycin-inhibitor; NTX, renal transplantation; PD, peritoneal dialysis; Tac, tacrolimus. (Fig. 2o,p) .
Severely diminished release of ICOS
À RTE T cells from the thymus in ESRD patients cannot be restored during renal replacement therapy (Fig. 3f) . Compared with ESRD patients, no significant changes concerning the composition of the ICOS À Tresp pool could be shown for dialysis patients (Fig. 3g ). (Fig. 3m,o) , indicating that RTE Treg/Tresp cells produce less proliferative CD31 + memory Treg/Tresp cells. Consequently, a strengthened differentiation of MN Treg/Tresp cells occurs (Fig. 3n,p (Fig. 4a) . After initiation of dialysis therapy, the percentages of ICOS + Treg/Tresp cells increased again without affecting their ratio (Fig. 4b) (Fig. 4c) . These conditions were maintained even after > 2 years after transplantation (Fig. 4d) (Fig. 4e) . After the initiation of dialysis therapy these conditions were maintained (Fig. 4f) . However, after transplantation, ICOS À Treg cells decreased sharply P < 0·001 P < 0·0001 (Fig. 4h) . , c) , ESRD patients compared with dialysis patients ( ) (e, g), dialysis patients compared with transplant recipients 2 years after transplantation ( ) (i, k) and transplant recipients < 2 years compared with transplant recipients > 2 years post transplantation ( ) (m, o). The figures present the regression lines concerning the changes in the percentages of the individual Treg/Tresp subsets with increasing age. Significant differences between the study groups and healthy volunteers are marked by black P-values. Significant differences between the different study groups are marked in the corresponding colours. A significant decrease/increase is marked by an arrow ( ). The proposed differentiation pathway of ICOS À RTE Treg/Tresp cells is shown in (b) and (d) for ESRD patients, in (f) and (h) for dialysis patients, in (j) and (l) for patients transplanted for < 2 years and in (n) and (p) for patients transplanted for > 2 years.
The suppressive activity of Treg cells is maintained in ESRD patients, but can hardly be preserved during renal replacement therapy
To examine whether there were differences in the suppressive activity of separated ICOS + and ICOS À Treg cells, the total CD4 + CD127 low+/À CD25 + Treg pool of 10 healthy volunteers (mean age 48 AE 9 years), 10 ESRD patients (mean age 50 AE 12 years), 10 dialysis patients (mean age 50 AE 14 years), 11 transplant recipients who were transplanted for > 2 years (mean age 49 AE 10 years) and 11 transplant recipients who were transplanted for < 2 years (mean age 52 AE 13 years) was isolated by magnetic-activated-cell-sorting and sorted into both Treg cell subsets (Fig. 5a) . Subsequently, the isolated ICOS + and ICOS À Treg cells were analysed separately for their suppressive capacity. Compared with healthy volunteers, we found that the suppressive activity of both Treg subsets was maintained in ESRD patients. In dialysis patients, the suppressive activity of both Treg subsets was significantly reduced. For ICOS À Treg cells, a significantly decreased suppressive activity was also revealed for both transplant patient groups (Fig. 5b,c) . The suppressive activity of ICOS + Treg cells could not be determined for transplant patients, due to an extremely low number of ICOS + Treg cells in these patients.
Discussion
The mechanisms leading to altered T-cell differentiation in ESRD patients are poorly understood. Meanwhile, these alterations, which correspond to a prematurely differentiated T-cell system, are expected to have consequences for the success of later kidney transplantation. 31 The most obvious symptom in ESRD patients is T-cell lymphopenia, due to a selective loss of circulating naive T cells and memory T cells attributed to increased activation-induced apoptosis. 6, 32, 33 Currently it is not known whether Treg and Tresp cells are equally affected. In this study, we show that the suppressive Treg cell function is initially completely preserved in ESRD patients, but that it is lost during the subsequent long-term renal replacement procedures. With regard to the fact that ESRD affects the thymic output of RTE Treg cells and RTE Tresp cells, we examined whether there were differences in the differentiation pathways of already distributed highly proliferative ICOS + RTE Treg/Tresp cells and less proliferative ICOS À RTE Treg/Tresp cells, which could explain this phenomenon. Figure 6 the recurrence of renal insufficiency in long-term transplant patients, which is frequently described in the literature. 20 However, our data did not show significant worsening of kidney function in long-term transplant patients compared with short-term transplant patients. Therefore, it will be of great importance to clarify whether such mechanisms may be involved in graft rejection, which is associated with a more severe loss of renal function and also of Treg cell function. 34 Meanwhile, it is widely accepted that renal insufficiency is closely related to premature T-cell senescence, even in children. 38 Recent studies also confirmed that neither frequencies nor the suppressive function of Treg cells were impaired in ESRD patients before and after the initiation of dialysis. 39 However, similar to our studies, Treg frequencies and Treg function were shown to be reduced in long-term kidney transplant patients. 40 Our findings indicate that, similar to aging 41 or pregnancy, 24, 28 renal insufficiency may provoke diminished thymic output of RTE Treg/Tresp cells and therefore accelerated peripheral differentiation of these cells. The increased peripheral Treg cell differentiation via initially tolerance-inducing pathways preserves the Treg function, as for example in old age, 29 during pregnancy 24, 28, 42 and presumably also in ESRD patients. However, in patients who had been exposed to renal replacement therapies for many years, these conditions cannot be sustained. In these patients, the switching in the differentiation of ICOS 43, 44 Further interesting Tcell populations, such as stem memory T cells, central memory T cells, effector memory T cells and terminally differentiated effector T cells were not the subject of our research and therefore may limit the informative value of our investigations. 45 Further studies, detecting the characteristic markers of stem memory T cells and central memory T cells, on MN and CD31 + memory cells may be necessary to identify preferred differentiation pathways of such cells under special clinical conditions. In summary, our data show for the first time how the CD4 + T helper cell pool changes over the years of renal replacement therapy and propose that timely transplantation of ESRD patients may significantly reduce the risk of rejection (Fig. 7) . Possibly, CD8 + T cells may also be affected by years of kidney failure. Further investigations regarding the differentiation of CD8 + RTE Treg/Tresp cells may be necessary to assess the influence of immunosenescence on the responsiveness of the entire Tcell system. From a clinical perspective, there are now numerous indications that the waiting time on dialysis is the strongest risk factor for poor renal transplant outcome, and that pre-emptive transplantation is associated with superior graft survival compared with pre-transplant dialysis. [46] [47] [48] 
